Pharmaceuticals
2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and DevicesÂ
The first half of 2024 ushered in a wave of transformative FDA approvals in cardiorenal metabolic health. Get up to date now!
July 17, 2024
The first half of 2024 ushered in a wave of transformative FDA approvals in cardiorenal metabolic health. Get up to date now!
In today’s society, the prevalence of obesity has become a
Although the U.S. Food and Drug Administration (FDA) approved a
“Insulin is a remedy primarily for the wise and not
Certain populations of ethnic and racial groups respond differently to
Almost all cardiometabolic providers across subspecialties rely on some degree
The chemical N-Nitrosodimethylamine, also referred to as NDMA, is a
Lifestyle interventions and preventative medications are central components of prevention
Statins, a class of lipid-lowering medications that are used in
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
